CRDF Q1 2022 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74,000+2.8% YoY

Gross Profit

$74,000100.0% margin

Operating Income

-$11M-14964.9% margin

Net Income

-$11M-14855.4% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-44.4%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$139M

Total Liabilities

$9M

Stockholders' Equity

$130M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74,000	$72,000	+2.8%
Gross Profit	$74,000	$72,000	+2.8%
Operating Income	-$11M	-$5M	-103.5%
Net Income	-$11M	-$5M	-112.3%